Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Clinical pregnancy rate
研究概览
简要总结
There are different controlled ovarian hyperstimulation protocols utilized in infertility patients. In this study, our aim is to specifically compare three protocols in poor responding infertility patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 42 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients will be considered eligible if they are poor ovarian responders according to the Bologna criteria (Ferraretti et al., 2011).
- •Two out of three of the following criteria are essential in order to classify a patient as poor ovarian responder:
- •advanced maternal age (≥40 years) or any other risk factor for poor ovarian response;
- •a poor ovarian response (≤3 oocytes with a conventional stimulation protocol); or
- •an abnormal ovarian reserve test (antral follicle count, <7 follicles or anti-Mullerian hormone, <1.1 ng/ml).
排除标准
- 未提供
研究组 & 干预措施
Combined 450
Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
干预措施: FSH 225IU and hMG 225IU (Drug)
Combined 300
Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
干预措施: FSH 150IU and hMG 150IU (Drug)
Letrozole and hMG
Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
干预措施: Letrozole 5mg and hMG 150IU (Drug)
结局指标
主要结局
Clinical pregnancy rate
时间窗: 8 weeks
次要结局
- Biochemical pregnancy rate(6 weeks)
- Number of transferable embryos(4 weeks)
- Number of oocytes retrieved(4 weeks)
研究者
Ercan Bastu
Associate Professor of Obstetrics and Gynecology
Istanbul University